SG Capital Management LLC acquired a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 409,104 shares of the medical instruments supplier’s stock, valued at approximately $9,205,000. OraSure Technologies makes up about 1.0% of SG Capital Management LLC’s holdings, making the stock its 17th largest position. SG Capital Management LLC owned 0.69% of OraSure Technologies at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. First Mercantile Trust Co. purchased a new position in OraSure Technologies in the 2nd quarter worth approximately $104,000. Pinebridge Investments L.P. purchased a new position in OraSure Technologies in the 2nd quarter worth approximately $131,000. Victory Capital Management Inc. lifted its holdings in OraSure Technologies by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 1,360 shares in the last quarter. Profund Advisors LLC lifted its holdings in OraSure Technologies by 2.8% in the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 293 shares in the last quarter. Finally, ETRADE Capital Management LLC purchased a new position in OraSure Technologies in the 2nd quarter worth approximately $193,000. 94.41% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently commented on OSUR. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, November 4th. ValuEngine cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Jefferies Group LLC cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. OraSure Technologies currently has a consensus rating of “Buy” and an average price target of $18.21.
In other news, insider Brian Smith sold 9,112 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $20.47, for a total transaction of $186,522.64. Following the sale, the insider now directly owns 32,477 shares of the company’s stock, valued at approximately $664,804.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mara G. Aspinall acquired 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were purchased at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the acquisition, the director now directly owns 5,000 shares in the company, valued at $71,150. The disclosure for this purchase can be found here. Insiders have sold a total of 58,035 shares of company stock worth $1,297,612 over the last ninety days. Insiders own 6.40% of the company’s stock.
Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) opened at $16.38 on Monday. The stock has a market capitalization of $993.41, a P/E ratio of 31.50, a PEG ratio of 3.14 and a beta of 1.39. OraSure Technologies, Inc. has a twelve month low of $8.21 and a twelve month high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.09. The business had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The company’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.11 EPS. analysts predict that OraSure Technologies, Inc. will post 0.42 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://transcriptdaily.com/2017/11/27/409104-shares-in-orasure-technologies-inc-osur-purchased-by-sg-capital-management-llc.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.